On January 16, 2024, medical device company Noctrix Health announced a $40 million Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation with strong support from insiders including OrbiMed and Treo Ventures. Wilson Sonsini Goodrich & Rosati advised Noctrix Health on the transaction.

Proceeds from the round will go towards the advancement of Nidra™ Tonic Motor Activation (TOMAC) therapy towards its eagerly anticipated launch in the U.S. market. Nidra™, a revolutionary new device, stands as the first and only approved treatment for drug-refractory Restless Legs Syndrome (RLS), a chronic condition that has debilitating impacts on sleep and quality of life of millions of adults worldwide. 

The Wilson Sonsini team that advised Noctrix Health on the transaction was led by James Huie, Minji Kim, and Samuel Silverstein.

For more information, please see Noctrix Health's news release. Additional coverage can be found on Medical Device Network.